LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study

  • Jadwiga Wedzicha, Karen Mezzi, Tim Ayers, Chau Thach, Robert Fogel, Francesco Patalano, Donald Banerji
  • European Respiratory Journal, September 2016, European Respiratory Society (ERS)
  • DOI: 10.1183/13993003.congress-2016.oa4833

The authors haven't yet claimed this publication.

Read Publication

In partnership with:

Link to European Respiratory Society (ERS) showcase